

Sent: 19 January 2011 10:08

Subject: RE: Final ACD and Evaluation Report and information on economic model for the appraisal of Lapatinib and trastuzumab - first line (with an aromatase inhibitor)MTA

Dear [REDACTED]

This confirms that Pfizer have no comments on the ACD, evaluation report or economic model for the above MTA.

Kind regards

[REDACTED]

Pfizer Ltd, Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS